XX, today, and Thank XXXX. of MindMed's Call. our everyone. press The open to results for quarter morning, Quarter you, Prior with XXXX of summary market Conference operator, Third Update Financial Welcome press Corporate and report a MindMed's September third of our quarterly good is Media on quarter Results our a issued XX-Q we the XXXX, website Securities to results the release and Commission. available is be with financial reporting to section release in Investors for Form filed the planned the Exchange and ended today and
our today our Executive Dr. Schond is Chief our Dan me Chief Financial and Karlin, Officer; Officer; Wernli, President. Joining Medical Greenway, Miriam Dr.
During followed provide the today's Q&A. on review the and update Schond will XXXX, business. for financial results call, XX, overview by I our September an Then will ended of quarter course
conference remind materially Before will from me differ by we in forward-looking begin, those may be such let during expressed you or call, Company's results statements. making indicated we statements. actual forward-looking this that
For refer of risks, recent our with Securities description and Commission. to the Exchange a filings please
and collaborators II MM-XXX was, which of treatment significant administration patients demonstrated clinically published on results in line significant Phase Hospital, results our disorders placebo-controlled Scientific conducted repeated the XX Top the in Journal anxiety late readout of our third study line across respect of continue to MM-XXX, we late September, its quarter, rapid, MM-XXX in MM-XXX optimization Enrollment trial continued With beneficial in quarter, we a Study of make University according trial from Phase potential treatment remains significant of to the clinical has anxiety by proof-of-concept to disorder. LSD and effects progress trial first generalized a of clinical progress II line in or to the enrollment Psychiatry. study, dosed of durable ASSIST we of During XXXX. also mitigate in depression. and course preclinical of with LSD. readout and In target the Phase ADHD our was our preparation progress continue our on dose review IIb the track with anxiety Getting LSD symptoms continued third investigator-initiated business. for peer low Phase I we of and XXXX. top top R(-)-MDMA or R&D at remain our the patient the a anxiety to plan, of for progress LSD in in In the Biological has the efforts in to to XXXX. in initiation program, and is
we targeting program R(-)-MDMA pharmacodynamic our the of This development insights and SDMA symptoms seeks expect Phase and initiated pharmacokinetic trial quarter, we clinical through of disorder. University MDMA I and, to in activity of Basel, dose valuable third we autism investigator-initiated X collaboration each will Hospital of provide of healthy RS volunteers. spectrum as progress study core our and levels dose into and assess and Additionally, MM-XXX X with level the sponsor a in
study being conducted collaborations continued progress, disorder UHB. depressive activities external treatment early to including in investigator-initiated our and R&D the Additionally, major have the LSD of at of
high-quality direction in MM-XXX's potential continues to to activity future provide LSD's UHP to data the generate brain clinical and Our the offer collaboration with modern, useful inform demonstrating in disorders. continues -- health opportunity development. to insights lab at
a and would focus financial discuss continue efficiency, and in moment indications position resources We to I efforts to on our to have our disclosed development the continued call and current we MM-XXX our take prioritize in intellectual and MM-XXX. further streamline second and efforts psychiatric quarter strategy. to our earnings and property also operational like
Hospital. and is As XXXXs LSD all discovered its LSD in chemist, Sandoz by are the aware, not was IP free available base. Accordingly, form you on our
of the could several converted XXXX, to which play believe meet XX on product proprietary in candidate LSD LSD pharmaceutical believe of third first a the we the modern pharmaceutical of and believe central original and granted, detartrate are patent of their claims innovations those we improvements optimized the However, date includes be active applications we that in standards. the protection applications, both In XXXX. development have in form meaningful and of detartrate ingredient, dosage MM-XXX. we MM-XXX. nonprovisional Should advancements the role be made quarter our This will we LSD on forms
providing value-driving device pursuit MSMS now the progress our turn over forward Schond and our We retain as candidates pipeline. digital filed a progress to have the Greenway, CFO, medical and of our our months and upcoming ahead. data we incredibly approach to and to execution highly candidates, of in we Under as manufacturing product. portfolio and discuss rights medicine aggressively MindMed intellectual pleased our programs, strategically to XXXX, is aligned rights year. on clinical our reaching call that look as product should studies seeking the development all financial the updates protect continue expand maximize I our for I'll continue eventual focused the And will of candidates. continued diverse products, with the approval to our a strategy we long-term end our has marketing. software, we we property, in medicine drug our who protection now remain broad product approved believe to IP eventually potential Monitoring of advance we'll for to MSMS plan System, of facilitate or to are will elements We're to be the our have the clinical of they further our and with We of anticipated key turn we our which product over our which platform to results. as continue digital Session regulatory and engagement milestones, the to access on platform,